Reducing the Risk of Re-Fracture in the Dialysis Population: Is it Time to Consider Therapy with PTH Analogues?

Seminars in Dialysis

Volumn 24, Issue 1, 2011, Pages 12-15

  Jamal, Sophie A ^a   Hodsman, Anthony B ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34];

AGED; ARTICLE; BLOOD; FRACTURE; HUMAN; HYPOPARATHYROIDISM; MIDDLE AGED; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

AGED; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; HYPOPARATHYROIDISM; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RISK FACTORS; TERIPARATIDE;

EID: 79951782544     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00817.x     Document Type: Article

References (36)

1. Kidney Disease: Improving Global Outcomes (KDIGO), CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76(Suppl 113):S1-S130, 2009
2. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz K-G, Young EW, Pisoni RL: Incidence and risk factors for hip and other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358-1366, 2006
3. Coco M, Rush DN: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115-1121, 2000
4. Erlichman M, Holohan TV: Bone densitometry: patients with end-stage renal disease. Health Technol Assess 8:1-27, 1996
5. Ott SM: Bone density in patients with chronic kidney disease stages 4-5. Nephrology 14:395-403, 2009
6. Canadian Institute for Health Information: Treatment of End-Stage Organ Failure in Canada 1998 to 2007 - CORR 2009 Annual Report (Ottawa, Ont.:CIHI, 2009. 2009. Ref Type: Report
7. Ensrud KE, Lui L-Y, Taylor BC, Ishani A, Schlipac MG, Stone KL, Cauley J, Jamal S, Antoniucci DM, Cummings SR for the Study of Osteoporotic Fractures Research Group: Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167:133-139, 2007
8. Lindberg JS, Moe SM: Osteoporosis in end-stage renal disease. Semin Nephrol 19:115-122, 1999
9. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149-156, 2010
10. Stehman-Breen CO, Sherrard DJ, Allem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200-2205, 2000
11. Block GA, Klasson PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
12. KDOQI: Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:1-201, 2003
13. Sanchez MC, Bajo A, Selgas R, Mate A, Millan I, Martinez E, Lopez-Barea F: Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 36:953-961, 2000
14. Block GA, Martin K, deFrancisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Drueke TB, Goodman WG: Cinecalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
15. Cunningham J, Danese MD, Olson K, Klasson PS, Chertow GM: Effects of the calcimimtic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793-1800, 2005
16. Reid IR, Miller PD, Brown JD, Kendler DL, Fahleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW: Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies†. J Bone Miner Res 25:2256-2265, 2010
17. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE: The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19:1430-1438, 2008
18. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR: Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Min Res 22:503-508, 2007
19. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Min Res 20:2105-2115, 2005
20. Jamal SA, Ljungren O, Stehman-Breen C, Cummings S, McClung MR, Goemaere S: The effects of denosumab on bone mineral density and fracture by level of renal function. Abstract. American Society of Bone and Mineral Research Annual Meeting 2010. J Bone Min Res. 25:s495, 2010.
21. Wetmore JB, Benet LZ, Kleinstuck D, Frassetto L: Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology. 10:393-399, 2005
22. Bergner R, Henrich D, Hoffman M, Schmidt-Gayk H, Lenz T, Upperkamp M: Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol. 21:510-516, 2008
23. Torregrosa J-V, Moreno A, Mas M, Ybarra J, Fuster D: Usefulness of pamidronate in severe secondary hypoparathyroidism undergoing hemodialysis. Kidney Int 63:S88-S90, 2003
24. Weisinger JR, Gonzalez L, Alvarez H, Hernandez E, Carlini RG, Capriles F, Cervino M, Martinis R, Paz-Martinez V, Bellorin-Font E: Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int 58:331-335, 2000
25. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, Sokalski A, Przedlacki J, Niemczyk S, Wlodarczyk D, Puka J, Switalski M: The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 14:1238-1243, 1999
26. Hernandez E, Valera r, Alonzo E, Bajares-Lilue M, Carlini RG, Capriles F, Martinis R, Bellorin-Font E, Weisenger JR: Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63:2269-2274, 2003
27. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen E, Mellstrom D, Ish-Shalom S, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Gaspar L, Mulder H, Halse J, Sawicki AZ, Genant H, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441, 2001
28. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler D, McLung MR, Miller PD, Olszynski W, Orwoll ES, Yuen CK: Parathyroid Hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703, 2005
29. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18:59-68, 2007
30. Martin TJ, Sims NA, Ng KW: Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int 19:1125-1138, 2008
31. Cejka D, Kodras K, Bader T, Haas M: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH(1-34)): a pilot study. Kidney Blood Press Res 33:221-226, 2010
32. Yamada S, Inaba M, Kurajo K, Imanishi Y, Ishimura E, Nishizawa Y: Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol 69:189-196, 2008
33. Lindsay R, Cosman F, Zhou H, Bostram MP, Shen VW, Cruz JD, Nieves JW, Dempster DW: A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366-373, 2006
34. Jamal SA, Gilbert J, Gordan C, Bauer DC: Cortical PQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21:543-548, 2006
35. Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, McMahon DJ, Leonard MB, Shane E: Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21:1371-1380, 2010
36. Tosteson AN, Melton LJ, Dawson-Hughes B, Bain S, Favus M, Khosla S, Lindsay R: Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-447, 2008